Story perspectives

NHS Puberty Blocker Trial Sparks Controversy Over Health Risks

11/27/2025

Summary

Story summary

Dr. Aidan Kelly, director of the UK's only regulated trans healthcare provider for under-18s, questions whether the National Health Service (NHS) puberty-blocker trial yields conclusive insights.
He says the trial treats puberty blockers alone and omits benefits from hormone therapy later.
The NHS trial was commissioned after a government ban and will study 220 participants.
Critics warn the ban could create a 'lost generation' seeking unregulated hormones.

1 of 1

Story summary

Dr. Aidan Kelly, director of the UK's only regulated trans healthcare provider for under-18s, questions whether the National Health Service (NHS) puberty-blocker trial yields conclusive insights.
He says the trial treats puberty blockers alone and omits benefits from hormone therapy later.
The NHS trial was commissioned after a government ban and will study 220 participants.
Critics warn the ban could create a 'lost generation' seeking unregulated hormones.